Investor Update

Basel, 19 September 2012

Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Recurrent Glioblastoma

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.